(f)' if BO, the quantity imported during tBe last three years, year-wise, alongwith average CIF price per Kg. per year;

(g) what is the indication for which this drug is being used; and

(h) what are the names of five leading formulators of this drug and what are the brands under which each is being sold?

THE MINISTER OP STATE IN THE MINISTRY OF HEALTH AND FAMILY WELFARE (KUMARI SAROJ KHAPARDE); (a) No, Sir.

(b) Does not arise.

(c) Ministry of Health and Family Welfare has not prepared any list of the Essential drugs on a national basis.

(d) Does not arise.

(e) and (f) Import of Trifluopera-rine Hcl during the last three years as available with this Ministry is gi-ren below;

Year	Qty. in kgs.	C.I.F. price per kg. in Rs.
1985-86 . .	1420	1500
1986-87. .	310	1909
1987-88 . .	1397	1835

(g) and (h) Trifluoperazine is used for gestrilis. Peptic Ulcers, Hyperacidity, Nervous dyspepsia and other gastr$_0$ intestinal disorders particularly caused or complicated °y mental/emotional factors.

Wames of five popular brands and their manufacturers are given in the enclosed statement.

Statement

Name of the brand	Name of Manufacturer
1. Triphenazin	M/s. Sun Pharma, Bombay.
2. Stelabid	M/s. Eskaycf, Bombay
3. Neoclam plus	M/s. INTAS, Bombay.
4. Trinicalm	. M/s. Torrent Labs. Ahmedabad.
S. Eskazine	. M/s. Eskay Pharma. Bombay.

Review of category-I drags for control of Leprosy and TB

740. SHRI ASHOK NATH VERMA: Will the Minister of HEALTH AND FAMILY WELFARE b$_e$,pleased to state:

(a) the names of the drugs recommended by the expert committee appointed by his Ministry to review category-I drugs needed for control of Leprosy and TR diseases;

(b) what are the names of drugs recommended by bis Ministry for inclusion under category-I of Price Control Order to the Department of Chemicals;

(c) whether it is a fact that certain drugs have not been included under category-I of Drugs Price Control Order;

(d) if so, the name$_s$ of those drug[1]?;

(e) what steps his Ministry has taken to get these drugs included

according to-Drug Policy 1986, and by when these would be included?

THE MINISTER OF STATE IN THE MINISTRY OF HEALTH AND FAMILY WELFARE (KUMARI SAROJ KHAPARDE); (a) The recommendations of the Expert Committee containing the review of drugs under Category I of Drugs (Price Control) Order, 1987 are under examination of the Ministry.

(b) The names Of drugs recommended by this Ministry for inclusion ■ in Category I on 4-6-87 is at Annexure (See Appendix CL, Annexure No. 88). This list was, however, shortened on the request of the Department of Chemicals and Petrochemicals which ig also annexed as Annexure [See Appendix CL, Annexure No. 39].

(c) to (e) The list of Category I drugs as amended by the Department of Chemicals and Petro-Chemicals in January, 1989 is at Annexure [See Appendix CL, Annexure No. 40]. Two drugs, namely Rifampicin and Paracetamol were re-classified . Three other drugs *viz.* Sodium Sulphaceta-mide Drops, Timolol Maleate and Oral Rehydration Salts were not in-eluded in Category I by the Department of Chemicals & Petro-Chemicals in the amended Drugs Prices Control Order, 1989, on the advice of the Kalkar Committee which was specially appointed for deciding the final inclusion of drugs for categorisation. The other drugs which were not included were vaccines required for the Universal Programme for Immunisation, drugs for the Maternal and Child Health Programme and the STD Control Programme. There are no drugs specifically for the AIDS-Control Programme. Th$_e$ Expert Committee set up by th$_e$ Ministry of Health and F. W. to review the listing of category I drugs has submitted its report. The recommendations of the Committee are under consideration of Ihe Ministry.

Import of Tirtprolidline, PoJymixin-B Sulphate

741. SHRI ASHOK NATH VERMA: Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state:

(a) whether Triprolidine, Polymixin-B Sulphate and Glipizide are being imported in the country; ■

(b) if so, what was the quantity imported of each during last three years, year-wise and the CIF import price of each;

(c) what is the indication for which each was cleared for human consumption in the country;

(d) the names of leading drug companies who are marketing formulations based on each drug;

(e) whether any of these drugs are used for any of the National Health Programmes;

(f) if so, the names of the drug* and the programme;

(g) whether his Ministry has declared any of these drugs non-essenn tial; and

(h)' if so, the names of those drugs?

THE MINISTER OF STATE IN THE MINISTRY OF HEALTH AND FAMILY WELFARE (KUMARI SAROJ KHAPARDE): (a) and (b) Information as available with this Ministry is given at Annexure [See Appenlix CL Annexure No. 41].

(c) and (d) A$_s$ per enclosed Statement (See below).

(e) No, Sir.

(f) Does not arise.

(g) No, Sir.

(h) Does- not arise.